cdk–4 antibody  (Beyotime)

Journal: Experimental and Therapeutic Medicine

Article Title: Purpurogallin carboxylic acid exhibits synergistic effects with 5‑fluorouracil on liver cancer cells in vitro by targeting ABCG2

doi: 10.3892/etm.2024.12564

Figure Lengend Snippet: PCA combined with 5-FU induces the G1 phase cell cycle arrest in liver cancer cells. (A) Flow cytometry was carried out to evaluate the cell cycle distribution in HepG2, Huh7 and Huh1 cells treated with DMSO, 10 µM PCA, 10 µM 5-FU or their combination. Western blot analysis was performed to detect the protein expression levels of CDK4 and CDK6 in (B) HepG2, (C) Huh7 and (D) Huh1 cells treated with DMSO, 10 µM PCA, 10 µM 5-FU or their combination. Reverse transcription- quantitative PCR was performed to detect the mRNA levels of CDK4 and CDK6 in (E) HepG2, (F) Huh7 and (G) Huh1 cells treated with DMSO, 10 µM PCA, 10 µM 5-FU or their combination. * P<0.05 and ** P<0.01. PCA, purpurogallin carboxylic acid; 5-FU, 5-fluorouracil; CDK, cyclin-dependent kinase.

Article Snippet: Following blocking with 8% skim milk powder in TBS-Tween-20 (0.1%) (TBST) for 2 h at 28 ̊C, the membranes were incubated with primary antibodies against cyclin-dependent kinase (CDK) 4 (1:2,000; cat no. 11026-1-AP), CDK6 (1:1,000; cat no. 14052-1-AP), ABCG2 (1:1,000; cat no. 27286-1-AP) and GAPDH (1:50,000; cat no. 60004-1-Ig) all from Proteintech Group, Inc. for 16 h at 4 ̊C.

Techniques: Flow Cytometry, Western Blot, Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction